革兰阴性菌感染:抗菌药物耐药性领导组的研究重点、成果与未来方向
抗菌药物耐药性领导组(ARLG)将革兰阴性菌耐药列为四大未满足医疗需求之一,其革兰阴性菌委员会开展前瞻性队列研究与干预试验。CRACKLE等项目提供了耐碳青霉烯肠杆菌目(CRE)的多中心风险因素与临床结局数据,CREST聚焦实体器官移植受者,磷霉素治疗产ESBL肠杆菌目感染的临床试验正在进行。
要点
- CRACKLE多中心数据描述美国哨兵医院CRE风险因素与临床结局。
- CREST为实体器官移植受者产ESBL肠杆菌目和CRE携带提供关键数据。
- 磷霉素口服降阶梯治疗复杂性尿路感染的临床试验评估临床疗效。
核心结论
- 革兰阴性菌耐药是紧迫挑战,ARLG通过队列与试验生成可指导临床决策的数据。
研究设计与样本
- ARLG革兰阴性菌委员会开展前瞻性队列研究与干预试验,包括CRACKLE、CREST等。
主要发现
- CRACKLE提供美国哨兵医院CRE风险因素与临床结局的多中心数据。
- CREST提供实体器官移植受者产ESBL肠杆菌目和CRE携带的关键数据。
临床怎么用
- 利用CRACKLE等队列数据识别CRE感染风险因素并指导临床管理。
- 参考CREST数据管理实体器官移植受者的产ESBL肠杆菌目和CRE携带。
- 等待磷霉素口服降阶梯治疗复杂性尿路感染的临床试验结果以指导用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial resistance in pathogenic gram-negative bacteria is one of the most pressing challenges in the field of infectious diseases and is one of 4 key areas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG). The mission of the Gram-Negative Committee is to advance our knowledge of these challenging infections and implement studies to improve patient outcomes. Studies have fallen primarily into 2 broad categories: prospective cohort studies and interventional trials. Among the observational studies, CRACKLE (Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae) has contributed seminal multicenter data describing risk factors and clinical outcomes of carbapenem-resistant Enterobacteriaceae (CRE) in sentinel US hospitals. Building on this success, CRACKLE II will expand the network to hospitals across the United States and Colombia. Similar protocols have been proposed to include Acinetobacter baumannii and Pseudomonas aeruginosa (SNAP and POP studies). In addition, the CREST study (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal data on extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management of this vulnerable patient population. Two clinical trials to define novel ways of using an existing antibiotic, fosfomycin, to treat ESBL-producing Enterobacteriaceae (one that has completed enrollment and the other in late protocol development) will determine the clinical efficacy of fosfomycin as step-down oral therapy to treat complicated urinary tract infections. Additional clinical studies and trials using immunotherapeutic or newly approved agents are also in the planning stage, with the main goals of generating actionable data that will inform clinical decision making and facilitate development of new treatment options for highly resistant gram-negative bacterial infections.
引用
- Doi Y, Bonomo RA, Hooper DC, et al. Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017. PMID: 28350901. doi:10.1093/cid/ciw829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。